Deprecated: Creation of dynamic property cls_session::$session_data_table is deprecated in /www/sites/www.188bio.com/index/systems/cls_session.php on line 49
Cellgs/PODS® Human EPO/PODS<sup>&reg;</sup> Human EPO, 50 million/PPH325-50188bio精品生物—专注于实验室精品爆款的电商平台 - 蚂蚁淘旗下精选188款生物医学科研用品
您好,欢迎您进入188进口试剂采购网网站! 服务热线:4000-520-616
蚂蚁淘商城 | 现货促销 | 科研狗 | 生物在线
产品资料

Cellgs/PODS® Human EPO/PODS<sup>&reg;</sup> Human EPO, 50 million/PPH325-50

PODS® Technology

PODS® proteins are made using an insect cell expression system in which the active protein is co-expressed alongside polyhedrin carrier protein. Polyhedrin forms microcrystals within insect cells which specifically capture the active protein to form a co-crystal complex. The active protein is captured in its nascent, natively folded form with limited scope for proteolytic degradation. Consequently, excellent levels of bioactivity are observed. The PODS® co-crystals provide a sustained release mechanism and can be used to functionalize surfaces. For further details, please refer to thePODS® Technology page.

Product Description

The product contains the polyhedrin protein co-crystalized with Human EPO. Erythropoietin is a glycoprotein hormone in the type I cytokine family. EPO is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules, and in much lower quantity, but functionally significant amounts, by fetal hepatocytes. EPO plays a role in erythropoiesis being responsible for stimulating proliferation and differentiation of erythroid progenitor cells.

Usage Recommendation

PODS® co-crystals provide a depot of proteins which are steadily secreted. It has been estimated that the biological activity of 50 million PODS® co-crystals generates the same peak dose as 3.3 μg of standard recombinant protein. However, at 5 days following the start of seeding the PODS® co-crystals, there are more than 50% of these peak levels still present in the culture system. Ultimately, the amount of PODS® co-crystals that is optimal for a particular experiment should be determined empirically. Based on previous data, we suggest using 50 million PODS® co-crystals in place of 3.3 μg of standard growth factor as a starting point."

To control for cross-reactivity with cells or as a negative control, we recommend using PODS® growth factors alongsidePODS® Empty crystals, as the latter do not contain or release cargo protein.

AA Sequence

MADVAGTSNR DFRGREQRLF NSEQYNYNNS KNSRPSTSLY KKAGFAPPRL ICDSRVLERY LLEAKEAENI TTGCAEHCSL NENITVPDTK VNFYAWKRME VGQQAVEVWQ GLALLSEAVL RGQALLVNSS QPWEPLQLHV DKAVSGLRSL TTLLRALGAQ KEAISPPDAA SAAPLRTITA DTFRKLFRVY SNFLRGKLKL YTGEACRTGD R

Alternative Names

Erythropoietin, EP, epoetin, MGC138142, MVCD2

Research Use Only

PODS® Limited Use Label License. A license applies for this product, please see Product User Guide below for details.
  • References
  • Documents
  • Contact Us
Product Details
Length211 aa
Molecular Weight23.6 kDa
StructureMonomer
SourceSpodoptera frugiperda (Sf9) cell culture
Accession NumberCAA26094
Endotoxin Level<0.06 EU/ml as measured by gel clot LAL assay
FormulationPODS® were lyophilized from a volatile solution
Reconstitution

PODS® co-crystals may be reconstituted at 200 million co-crystals/ml in water. 20% glucose has a buoyant density closer to PODS® co-crystals and can be useful for aliquoting.

PODS® co-crystals are highly stable when stored in aqueous solution (pH range 6 - 8).

Stability and StorageUpon receipt, store at 4°C. PODS® co-crystals are stable for at least 1 year when dry and 6 months when resuspended.

References

Fasséli Coulibaly, Elaine Chiu, Keiko Ikeda, Sascha Gutmann, Peter W. Haebel, Clemens Schulze-Briese, Hajime Mori, and Peter Metcalf. The molecular organization of cypovirus polyhedra. (2007)Nature. 446: 97-101.

Rey FA. Virology: Holed up in a natural crystal. (2007)Nature. 446: 35-37.

Mori H. Immobilization of Bioactive Growth Factors into Cubic Proteinous Microcrystals (Cypovirus Polyhedra) and Control of Cell Proliferation and Differentiation. (2010)NSTI-Nanotech. 3: 222-225.

Satoshi Abe, Hiroshi Ijiri, Hashiru Negishi, Hiroyuki Yamanaka, Katsuhito Sasaki, Kunio Hirata, Hajime Mori, and Takafumi Ueno. Design of Enzyme-Encapsulated Protein Containers by In-Vivo Crystal Engineering. (2015)Advanced Materials. 27(48): 7951-7956.

Documents

PPH325 Datasheet.pdfPODS User Guide.pdfPODS MSDS.pdf

新闻动态
行业前沿
技术文章
最新产品